Following Glaukos’ (GKOS) earnings report, attention now turns to the regulatory processes for core growth products like iDose and iStent Infinite, outlined more broadly in our March 1 deep dive on issues surrounding their approval, coding, coverage, and reimbursement.
Policy & Legal, Research
Glaukos (GKOS): Pipeline Policy Pathway
04 March 2023